SyntheticMR (SYNT) Q2 2026 earnings summary

Executive summary

• Net sales for Q2 2026 increased by 13% year-over-year to 14.0 MSEK, with strong growth in cNeuro and APAC regions.

• Operating profit improved to -6.5 MSEK from -8.6 MSEK, and net loss narrowed to -6.1 MSEK from -10.4 MSEK year-over-year.

• Cash and cash equivalents rose to 28.3 MSEK at quarter-end, up from 19.4 MSEK last year.

• Regulatory approval for CMRI ARIA was obtained in the UK and Switzerland during the quarter.

• Leadership changes in the US organization and recruitment of a global CCO to strengthen sales and marketing.

Financial highlights

• Q2 net sales: 13,991 TSEK (up 13% year-over-year); H1 net sales: 27,084 TSEK (up 2%).

• Q2 operating profit: -6,457 TSEK (margin -46%); H1 operating profit: -12,726 TSEK (margin -47%).

• Q2 net profit: -6,089 TSEK; H1 net profit: -12,275 TSEK.

• Cash flow from operating activities in Q2: -2,570 TSEK; H1: -6,202 TSEK.

• Shareholders’ equity at period end: 125,707 TSEK; equity/assets ratio: 78.2%.

Outlook and guidance

• Focus on achieving profitability through increased sales and disciplined cost control.

• Capital from the rights issue is being used to strengthen sales, market presence, and strategic partnerships.

• Ongoing FDA review for cMRI ARIA in the US; awaiting further feedback.